Lymphoma Clinical Trials in New York

Showing 521-540 of 620 trials

A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies

NCT00475917

The purpose of this study is to determine a safe dose of XL844 in combination with gemcitabine, how often it should be taken, and how well people with cancer tolerate the combination of gemcitabine and XL844.

CancerLymphoma

Exelixis28 participantsStarted May 2007

New York, New York, United States • Houston, Texas, United States

TERMINATEDPhase 2< 1 mile

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

NCT00274651

Open-label, non-randomized trial to assess the effectiveness of PXD101 in patients with recurrent or refractory cutaneous or peripheral and other types of T-cell lymphomas. PXD101 is a new, potent histone deacetylase (HDAC) inhibitor. Patients are treated with belinostat(PXD101) 1000 mg/m2 on days 1-5 of a 21 day cycle.

Cutaneous T-Cell LymphomaPeripheral T-Cell LymphomaNon-Hodgkin's Lymphoma

Valerio Therapeutics53 participantsStarted Jan 2006

Stanford, California, United States • New Haven, Connecticut, United States • Lenexa, Kansas, United States +12 more locations

A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

Lymphoma Trials in Other Cities

Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

Unrelated Donor Transplant for Malignant and Non-Malignant Disorders

Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

Longitudinal Survey Analysis in Lymphoma Survivors

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma

S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Other Conditions in New York